ethyl 3-methyl-2-pyridineacetate | 5552-80-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: ethyl 3-methyl-2-pyridineacetate
• 英文别名: ethyl 2-(3-methylpyridin-2-yl)acetate；Ethyl-3-methyl-2-pyridylacetat
• CAS: 5552-80-7
• 化学式: C₁₀H₁₃NO₂
• mdl: MFCD10698590
• 分子量: 179.219
• InChiKey: XNYIYVMPRJBSMY-UHFFFAOYSA-N

物化性质

• 熔点：
  125.5-126.5 °C
• 沸点：
  141-145 °C(Press: 18 Torr)
• 密度：
  1.065±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 3-methyl-2-pyridineacetate 在 platinum(IV) oxide 氢气 、 溶剂黄146 、 苯甲醚 、 三苯基膦 、 三氟乙酸 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 20.0 ℃ 、310.26 kPa 条件下， 反应 31.0h， 生成 7-Chloro-3-(3,5-dimethyl-phenyl)-4-[2-(3-methyl-piperidin-2-yl)-ethoxy]-6-nitro-1H-quinolin-2-one
  参考文献：
  名称：

  Syntheses and structure–activity relationship studies of piperidine-substituted quinolones as nonpeptide gonadotropin releasing hormone antagonists

  摘要：

  Syntheses and structure-activity relationships of piperidine-substituted quinolones as nonpeptide gonadotropin releasing hormone antagonists are described. Some of substituents on the piperidine ring that were investigated included a fused phenyl group, a (6R)-trifluoromethyl group, (6S) and (6R)-methyl group. This study showed that GnRH binding potency was tolerated by a small group at the 6-position of the piperidine, and blocking the 6-position by a trifluoromethyl group reduced clearance rate and increased oral bioavailability. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.101
• 作为产物：
  描述：

  2,3-二甲基吡啶 、 碳酸二乙酯 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 以46 %的产率得到ethyl 3-methyl-2-pyridineacetate
  参考文献：
  名称：

  铜催化 2-烷基氮杂芳烃和靛红衍生的酮亚胺的直接不对称曼尼希反应

  摘要：

  以手性Cu-双(恶唑啉)配合物为催化剂，实现了2-烷基氮杂芳烃和酮亚胺的第一个直接催化不对称曼尼希反应。 2-烷基吡啶与靛红衍生的酮亚胺的不对称加成反应顺利进行，得到带有 3-氨基-3,3-二取代羟吲哚基序的 α,β-官能化 2-取代吡啶，结果优异（≤99% 收率，99:1 dr和 98% ee）。该催化体系还扩展到作为酮亚胺不对称曼尼希反应的亲核试剂的2-烷基苯并噻唑。

  DOI：

  10.1021/acs.orglett.4c00227

文献信息

• Metal-free synthesis of imidazo[1,5-<i>a</i>]pyridines <i>via</i> elemental sulfur mediated sequential dual oxidative Csp³–H amination
  作者：Jie Sheng、Jidan Liu、He Zhao、Liyao Zheng、Xingchuan Wei

  DOI：10.1039/c8ob01391h

  日期：——

  A simple and efficient approach has been developed for the synthesis of imidazo[1,5-a]pyridines using the elemental sulfur mediated sequential dual oxidative Csp3–H amination of 2-pyridyl acetates and amines under metal- and peroxide-free conditions. Broad substrate scope, operational simplicity and gram-scale ability make this chemistry very practical.

  已经开发了一种简单有效的方法，用于在无金属和无过氧化物的条件下，使用元素硫介导的乙酸2-吡啶酯和胺的连续双氧化Csp 3 -H胺化来合成咪唑并[1,5- a ]吡啶。广泛的底物范围，操作简便和克级能力使这种化学非常实用。
• Synthesis and evaluation of novel phenoxypropanolamine derivatives containing acetanilides as potent and selective β3-adrenergic receptor agonists
  作者：Tatsuya Maruyama、Kenichi Onda、Masahiko Hayakawa、Norio Seki、Takumi Takahashi、Hiroyuki Moritomo、Takayuki Suzuki、Tetsuo Matsui、Toshiyuki Takasu、Itsuro Nagase、Mitsuaki Ohta

  DOI：10.1016/j.bmc.2009.03.044

  日期：2009.5

  In the search for potent and selective human β3-adrenergic receptor (AR) agonists as potential drugs for the treatment of obesity and noninsulin-dependent (type II) diabetes, a novel series of phenoxypropanolamine derivatives containing acetanilides were prepared and their biological activities were evaluated at the human β3-, β2-, and β1-ARs. Several of the analogues (21a, 21b, and 27a) exhibited

  在寻找有效和选择性的人β3-肾上腺素能受体（AR）激动剂作为治疗肥胖和非胰岛素依赖型（II型）糖尿病的潜在药物时，制备了一系列新的含乙酰苯胺的苯氧基丙醇胺衍生物，并对其生物学活性进行了评估。在人类β3-，β2-和β1-ARs中。几个类似物（21a，21b和27a）在β3-AR上显示出强大的激动活性。在本文所述的化合物中，发现N-甲基-1-苄基咪唑-2-基乙酰苯胺衍生物（21b）是最有效和选择性最强的β3-AR激动剂，EC 50β1-或β2-AR的值仅为0.28μM，且无激动活性。另外，在啮齿动物糖尿病模型中21b显示出显着的降血糖活性。
• COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS
  申请人：Fuchs Klaus

  公开号：US20120115863A1

  公开（公告）日：2012-05-10

  The invention relates to novel cycloalkyl- or cycloalkenyl-substituted pyrazolopyrimidinones of formula (I), wherein Ā is selected from the group A 1 consisting of a C 3 -C 8 -cycloalkyl group or a C 4 -C 8 -cycloalkenyl group, whereby the members of C 3 -C 8 -cycloalkyl group being selected from the group of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl and cyclooctanyl; and the members of the C 4 -C 8 -cycloalkenyl group, being selected from cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclopentadienyl, cyclohexadienyl, cycloheptadienyl, cyclooctadienyl, cycloheptatrienyl, cyclooctathenyl, cyclooctatetraenyl. The new compounds shall be used for the manufacture of medicaments, in particular medicaments for improving perception, concentration, learning and/or memory in patients in need thereof. Chemically, the compounds are characterised as pyrazolopyrimidinones with a cycloalkyl-moiety directly bound to the 1 position of the pyrazolopyrimidinone and a second substituent in the 6 position which is bound via an optionally substituted methylene-bridge. Further aspects of the present invention refer to a process for the manufacture of the compounds and their use for producing medicaments.

  该发明涉及具有以下结构的新型环烷基或环烯基取代的吡唑吡咪啉酮化合物（I），其中Ā选自A1组中的C3-C8环烷基或C4-C8环烯基，其中C3-C8环烷基组成员选自环丙基、环丁基、环戊基、环己基、环庚基和环辛基；而C4-C8环烯基组成员选自环丁烯基、环戊烯基、环己烯基、环庚烯基、环辛烯基、环戊二烯基、环己二烯基、环庚二烯基、环辛二烯基、环庚三烯基、环辛烷基、环辛四烯基。这些新化合物可用于制造药物，特别是用于改善患者感知、注意力、学习和/或记忆的药物。从化学上讲，这些化合物被描述为在吡唑吡咪啉酮的1位上直接连接有环烷基基团，并且在6位上通过一个可选取代的亚甲基桥连接有第二取代基。该发明的进一步方面涉及一种制造这些化合物的方法以及它们用于生产药物的用途。
• HETEROCYCLIC COMPOUND AND USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20190300536A1

  公开（公告）日：2019-10-03

  The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

  本发明提供一种具有对包含NR2B亚基的NMDA受体具有拮抗作用的杂环化合物，预计可作为预防或治疗重度抑郁症、双相情感障碍、偏头痛、疼痛、痴呆症的行为和心理症状等的药物。本发明涉及一种由以下式（I）表示的化合物：其中每个符号如描述中所述，或其盐。
• Amide derivatives or salts thereof
  申请人：Yamanouchi Pharmaceutical Co., Ltd.

  公开号：US06346532B1

  公开（公告）日：2002-02-12

  Amide derivatives represented by general formula (I) or salts thereof wherein each symbol has the following meaning: ring B: an optionally substituted heteroaryl optionally fused with a benzene ring; X: a bond, lower alkylene or lower alkenylene optionally substituted by hydroxy or lower alkyl, carbonyl, or a group represented by —NH— (when X is lower alkylene optionally substituted by lower alkyl which may be bonded to the hydrogen atom bonded to a constituent carbon atom of ring B to form lower alkylene to thereby form a ring); A: a lower alkylene or a group represented by -(lower alkylene)—O—; R1a and R1b: the same or different and each hydrogen or lower alkyl; R2: hydrogen or halogeno; and Z: nitrogen or a group represented by ═CH—. The compounds are useful as a diabetes remedy which not only functions to both accelerate the secretion of insulin and enhance insulin sensitivity but has an antiobestic action and an antihyperlipemic action based on its selective stimulative action on a &bgr;3 receptor.

  通用公式（I）表示的酰胺衍生物或其盐，其中每个符号的含义如下：环B：可选地取代的杂环芳基，可选地与苯环融合；X：键，较低的烷基或烯基，可选地取代为羟基或较低的烷基，酰基，或由—NH—表示的基团（当X为较低的烷基时，可选地取代为较低的烷基，可能与环B上的一个碳原子上的氢原子结合以形成较低的烷基从而形成一个环）；A：较低的烷基或由-(较低的烷基)—O—表示的基团；R1a和R1b：相同或不同，各为氢或较低的烷基；R2：氢或卤素；Z：氮或由═CH—表示的基团。这些化合物可用作糖尿病疗法，不仅能加速胰岛素的分泌和增强胰岛素敏感性，还具有抗肥胖作用和抗高脂血症作用，这是基于其对β3受体的选择性刺激作用。